False positive cervical HPV screening test results

Schiffman, Mark; Sanjosé, Sílvia de

doi:10.1016/j.pvr.2019.04.012

Cited by 35 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, a large number of methods for screening CIN or early CC have been developed, such as HPV DNA testing [8], papanicolaou (pap) smear [9], liquid-based cytology (LBC) [10], joint test, and colposcopy, leading to the reduction of the incidence and mortality rate of CC [11][12][13]. Nevertheless, existing screening methods were complained of some limitations, including false-positive rate [14] or false-negative rate [15][16][17], possibility of overdiagnosis [18], probability of missed diagnosis [19], invasive procedure (cervical scraping or tissue biopsy), the difference between interobserver and intraobserver, and variation among pathologists [20], which made the triage of screening CC more complicated [21]. Therefore, it is extremely imperative to find simple, noninvasive, and feasible biomarkers for identification of CIN and early CC.…”

Section: Introductionmentioning

confidence: 99%

Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta‐Analysis

Jiang

Hu²,

Zuo

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Cervical cancer (CC) is one of the most common female malignant tumors. And cervical intraepithelial neoplasia (CIN) is the precancerous lesion of CC, which can progress to invasive CC. MicroRNAs (miRNAs) have been found to be potential diagnostic biomarkers for CIN or CC. However, recently, the lack of sufficient studies about the diagnostic value of miRNAs for CIN made it challenging to separately investigate the diagnostic efficacy of miRNAs for CIN. Likewise, the conclusions among those studies were discordant. Therefore, we conducted this meta-analysis, aimed at evaluating the diagnostic efficacy of miRNAs for CIN and CC patients. Methods. Literature search was performed in PubMed, Embase, and Web of Science databases. Pooled sensitivity, specificity, and other diagnostic parameters were calculated through Stata 14.0 software. Furthermore, subgroup analyses and metaregression analysis were conducted to explore the main sources of heterogeneity. Results. Ten articles covering 50 studies were eligible, which included 5,908 patients and 4,819 healthy individuals. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were 0.81 (95% CI, 0.77-0.85), 0.86 (95% CI, 0.83-0.89), 5.9 (95% CI, 4.5-7.7), 0.22 (95% CI, 0.17-0.28), 27 (95% CI, 17-44), and 0.91 (95% CI, 0.88-0.93), respectively. Additionally, the ethnicity and internal reference were the main sources of heterogeneity. Conclusions. Circulating miRNAs can be a promising noninvasive diagnostic biomarker for CIN and early CC, especially miR-9 and miR-205, which need to be verified by large-scale studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta‐Analysis

Jiang

Hu²,

Zuo

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The HPV test was performed with the Hybrid Capture 2 test technology (HC2; Qiagen, Gaithersburg, MD, USA) which detects 13 high-risk HPV types: 16,18,31,33,35,39,45,51,52, 56, 58, 59 and 68. A positive result was considered if attained or exceeded the FDA-approved threshold of 1.0 relative light unit (RLU/CO).…”

Section: Screening Tests and Gold Standard Testmentioning

confidence: 99%

“…However, having a screening test with a higher sensitivity but a lower specificity leads to overdetection and needs to be balanced by the benefits of an early detection. To avoid detection of HPV positive cases that are unlikely to develop cervical cancer, several authors have proposed to restrict the number of HPV types included in the HPV assays, given that the risk of developing a CIN3+ is very low for some genotypes such as 39, 51, 56, 59, 68 [33,34]. Recent studies have seen that the risk of developing a 7-year CIN3+ for these types is less than 5% and 80% of these infections are no longer detected in three years [34].…”

Section: Plos Onementioning

confidence: 99%

Long-term protection of HPV test in women at risk of cervical cancer

et al. 2020

View full text Add to dashboard Cite

Objective To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2 +) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. Methods In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Results Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women

show abstract

“…It also captured other less carcinogenic types such as HPV 39, 59, 68, 51 and 56, as in the study performed by Secondy et al 35 The higher HPV positivity rate found by care HPV could be due to the test’s ability to identify these less carcinogenic HPV types. This may be associated with a waste of resources, which may especially be a problem in LMICs, where economic means are constrained 16 . While bearing this in mind, limiting the range of HPV types in the care HPV test to the most carcinogenic ones to improve the cost‐effectiveness of the testing might be considered.…”

Section: Discussionmentioning

confidence: 99%

Agreement between careHPV and hybrid capture 2 in detecting high‐risk HPV in women in Tanzania

Katanga

Kjær

Manongi

et al. 2021

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction Visual inspection of the cervix with acetic acid is used to control the burden of cervical cancer in low‐ and middle‐income countries. This method has some limitations and HPV DNA testing may be an alternative, but it is expensive and requires a laboratory setup. Cheaper and faster HPV tests have been developed. This study describe the agreement between a fast HPV test (careHPV) and hybrid capture 2 (HC2) in detection of high‐risk HPV among Tanzanian women. Material and methods The study involved women attending routine cervical cancer screening at the Ocean Road Cancer Institute and Kilimanjaro Christian Medical Centre in Tanzania. The women were offered HIV testing. Two cervical samples were subsequently obtained; the first sample was processed at the clinics using careHPV and the second sample was transported to Denmark and Germany for cytology and HC2 analysis. Kappa statistic was calculated to assess the agreement between careHPV and HC2. The sensitivity, specificity and predictive values of careHPV were calculated using HC2 as reference. The analyses were done for the overall study population and stratified by testing site and HIV status. Results A total of 4080 women were enrolled, with 437 being excluded due to invalid information, lack of careHPV or HC2 results. Overall agreement between the tests was substantial with a kappa value of 0.69 (95% confidence interval [CI] 0.66‐0.72). The sensitivity and specificity of careHPV was 90.7% (95% CI 89.6‐91.8) and 84.2% (95% CI 81.2–86.8), respectively. The agreement was similar in the stratified analyses where the kappa values were 0.75 (95% CI 0.70‐0.79) in women aged 25‐34, 0.66 (95% CI 0.62‐0.70) in women aged 35–60, 0.73 (95% CI 0.70‐0.77) at the Ocean Road Cancer Institute, 0.64 (95% CI 0.60‐0.69) at the Kilimanjaro Christian Medical Center, 0.73 (95% CI 0.68‐0.79) in HIV‐positive and 0.66 (95% CI 0.63‐0.70) in HIV‐negative women. The kappa value of 0.64 (95% CI 0.39‐0.88) for cervical high‐grade lesions indicates a substantial agreement between careHPV and HC2 in detecting HPV among women with cervical high‐grade lesions. Conclusions A substantial agreement was found between careHPV and HC2 in detecting HPV overall as well as detecting HPV among women with cervical high‐grade lesions. However, given the limited resources available in low and middle‐income countries, the HPV testing assay should be weighed against the cost‐effectiveness of the test.

show abstract

False positive cervical HPV screening test results

Cited by 35 publications

References 25 publications

Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta‐Analysis

Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta‐Analysis

Long-term protection of HPV test in women at risk of cervical cancer

Agreement between careHPV and hybrid capture 2 in detecting high‐risk HPV in women in Tanzania

Contact Info

Product

Resources

About